BeOne Medicines (BEIGF) Cost of Revenue (2017 - 2026)

BeOne Medicines (BEIGF) has reported Cost of Revenue for 10 consecutive years, with $174.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 6.03% year-over-year to $174.5 million in Q2 2026; TTM through Jun 2026 was $680.7 million, a 3.03% increase from a year earlier, with the FY2025 full-year figure at $668.5 million, up 12.53% from the prior year.
• Cost of Revenue was $174.5 million for Q2 2026 at BeOne Medicines, up from $167.2 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $196.5 million in Q3 2025 and troughed at $65.2 million in Q1 2022.
• A 5-year average of $126.2 million and a median of $131.5 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 99.59% in 2022 and slipped 11.3% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $73.5 million in 2022, then soared by 43.95% to $105.8 million in 2023, then soared by 51.71% to $160.6 million in 2024, then slipped by 11.3% to $142.4 million in 2025, then gained by 22.54% to $174.5 million in 2026.
• The last three Cost of Revenue figures came in at $174.5 million (Q2 2026), $167.2 million (Q1 2026), and $142.4 million (Q4 2025), per Business Quant data.